S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.69 (+1.02%)
AAPL   146.61 (+1.22%)
MSFT   306.87 (+0.87%)
FB   335.39 (+3.27%)
GOOGL   2,851.10 (+0.84%)
TSLA   869.59 (+3.15%)
AMZN   3,445.90 (+1.08%)
NVDA   221.92 (+1.51%)
BABA   167.16 (-0.50%)
NIO   39.48 (+4.69%)
CGC   13.20 (-1.12%)
GE   104.17 (-0.23%)
MU   67.18 (-0.74%)
AMD   116.19 (+3.63%)
T   25.32 (-1.48%)
F   15.58 (-0.76%)
ACB   6.93 (-1.42%)
DIS   171.30 (-2.92%)
PFE   41.34 (-0.36%)
BA   216.88 (-0.07%)
AMC   43.01 (+5.57%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.69 (+1.02%)
AAPL   146.61 (+1.22%)
MSFT   306.87 (+0.87%)
FB   335.39 (+3.27%)
GOOGL   2,851.10 (+0.84%)
TSLA   869.59 (+3.15%)
AMZN   3,445.90 (+1.08%)
NVDA   221.92 (+1.51%)
BABA   167.16 (-0.50%)
NIO   39.48 (+4.69%)
CGC   13.20 (-1.12%)
GE   104.17 (-0.23%)
MU   67.18 (-0.74%)
AMD   116.19 (+3.63%)
T   25.32 (-1.48%)
F   15.58 (-0.76%)
ACB   6.93 (-1.42%)
DIS   171.30 (-2.92%)
PFE   41.34 (-0.36%)
BA   216.88 (-0.07%)
AMC   43.01 (+5.57%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.69 (+1.02%)
AAPL   146.61 (+1.22%)
MSFT   306.87 (+0.87%)
FB   335.39 (+3.27%)
GOOGL   2,851.10 (+0.84%)
TSLA   869.59 (+3.15%)
AMZN   3,445.90 (+1.08%)
NVDA   221.92 (+1.51%)
BABA   167.16 (-0.50%)
NIO   39.48 (+4.69%)
CGC   13.20 (-1.12%)
GE   104.17 (-0.23%)
MU   67.18 (-0.74%)
AMD   116.19 (+3.63%)
T   25.32 (-1.48%)
F   15.58 (-0.76%)
ACB   6.93 (-1.42%)
DIS   171.30 (-2.92%)
PFE   41.34 (-0.36%)
BA   216.88 (-0.07%)
AMC   43.01 (+5.57%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.69 (+1.02%)
AAPL   146.61 (+1.22%)
MSFT   306.87 (+0.87%)
FB   335.39 (+3.27%)
GOOGL   2,851.10 (+0.84%)
TSLA   869.59 (+3.15%)
AMZN   3,445.90 (+1.08%)
NVDA   221.92 (+1.51%)
BABA   167.16 (-0.50%)
NIO   39.48 (+4.69%)
CGC   13.20 (-1.12%)
GE   104.17 (-0.23%)
MU   67.18 (-0.74%)
AMD   116.19 (+3.63%)
T   25.32 (-1.48%)
F   15.58 (-0.76%)
ACB   6.93 (-1.42%)
DIS   171.30 (-2.92%)
PFE   41.34 (-0.36%)
BA   216.88 (-0.07%)
AMC   43.01 (+5.57%)

Compare Stocks

Date Range: 

 AbbVieNovartisMerck & Co., Inc.AstraZenecaEli Lilly and
SymbolNYSE:ABBVNYSE:NVSNYSE:MRKNASDAQ:AZNNYSE:LLY
Price Information
Current Price$107.51$82.32$77.13$59.23$239.14
50-Day Moving Average$111.93$87.38$76.42$58.62$246.59
52-Week Low$79.11$77.04$70.89$46.48$129.21
52-Week High$121.53$98.52$85.60$61.34$275.87
MarketRank™
Overall Score3.42.23.02.72.9
Analysis Score3.43.13.44.42.5
Community Score4.94.34.55.04.8
Dividend Score5.02.54.22.53.3
Ownership Score2.50.01.70.02.5
Earnings & Valuation Score1.31.31.31.91.3
Analyst Ratings
Consensus RecommendationBuyHoldBuyBuyBuy
Consensus Price Target$126.67$108.50$93.31$124.00$259.06
% Upside from Price Target17.82% upside31.80% upside20.98% upside109.35% upside8.33% upside
Trade Information
Market Cap$189.99 billion$184.13 billion$195.24 billion$183.51 billion$229.34 billion
Beta0.820.540.410.530.25
Average Volume6,998,1201,911,11312,324,5809,546,1483,444,544
Sales & Book Value
Annual Revenue$45.80 billion$48.66 billion$47.99 billion$26.62 billion$24.54 billion
Price / Sales4.153.784.076.899.35
Cashflow$13.84 per share$8.12 per share$7.77 per share$3.38 per share$8.94 per share
Price / Cash7.7710.149.9317.5426.76
Book Value$7.42 per share$24.76 per share$10.04 per share$5.96 per share$6.09 per share
Price / Book14.493.327.689.9439.27
Profitability
Net Income$4.62 billion$8.07 billion$7.07 billion$3.20 billion$6.19 billion
EPS$10.56$5.75$5.94$2.01$7.93
Trailing P/E Ratio28.9820.8435.2241.1335.85
Forward P/E Ratio7.7312.3012.2816.7328.17
P/E Growth2.012.072.161.211.86
Net Margins12.40%17.83%11.48%12.77%22.71%
Return on Equity (ROE)154.24%25.25%50.93%40.02%119.12%
Return on Assets (ROA)14.10%10.74%16.15%8.82%15.81%
Dividend
Annual Payout$5.20$2.08$2.60$1.37$3.40
Dividend Yield4.84%2.53%3.37%2.31%1.42%
Three-Year Dividend Growth84.37%13.60%31.22%N/A42.31%
Payout Ratio49.24%36.17%43.77%68.16%42.88%
Years of Consecutive Dividend Growth49 Years2 Years10 YearsN/A7 Years
Debt
Debt-to-Equity Ratio5.89%0.46%0.72%1.54%2.21%
Current Ratio0.91%0.80%1.31%1.23%1.15%
Quick Ratio0.79%0.56%1.06%1.01%0.89%
Ownership Information
Institutional Ownership Percentage65.82%9.90%71.83%13.88%81.65%
Insider Ownership Percentage0.09%0.01%0.32%N/A0.13%
Miscellaneous
Employees2,020105,79473,50076,1002,020
Shares Outstanding1.77 billion2.24 billion2.53 billion3.10 billion959.03 million
Next Earnings Date10/29/2021 (Confirmed)10/26/2021 (Confirmed)10/28/2021 (Confirmed)11/12/2021 (Confirmed)10/26/2021 (Confirmed)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
Outlook on the Protein Therapeutics Global Market to 2026 - by Product, Therapy Area, Function and Region - ResearchAndMarkets.comOutlook on the Protein Therapeutics Global Market to 2026 - by Product, Therapy Area, Function and Region - ResearchAndMarkets.com
finance.yahoo.com - October 18 at 2:26 PM
PFE vs. LLY: Which Stock Should Value Investors Buy Now?PFE vs. LLY: Which Stock Should Value Investors Buy Now?
finance.yahoo.com - October 18 at 2:26 PM
Osteoarthritis Drugs Industry May Set New Growth Story 2027|Johnson & Johnson, Pfizer, Eli Lilly, AbbottOsteoarthritis Drugs Industry May Set New Growth Story 2027|Johnson & Johnson, Pfizer, Eli Lilly, Abbott
openpr.com - October 18 at 9:25 AM
Quest Diagnostics to Introduce Ki-67 IHC MIB-1 pharmDx, the First Companion Diagnostic for Eli Lilly and Companys Verzenio® (abemaciclib), a CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast CancerQuest Diagnostics to Introduce Ki-67 IHC MIB-1 pharmDx, the First Companion Diagnostic for Eli Lilly and Company's Verzenio® (abemaciclib), a CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer
prnewswire.com - October 18 at 7:18 AM
Why CT Congress members and pharma giants disagree about drug pricesWhy CT Congress members and pharma giants disagree about drug prices
stamfordadvocate.com - October 17 at 9:31 AM
Oncology - Pharmaceutical, Eli LillyOncology - Pharmaceutical, Eli Lilly
thepharmaletter.com - October 16 at 11:35 PM
Oncology - Pharmaceutical, Eli Lilly, ResearchOncology - Pharmaceutical, Eli Lilly, Research
thepharmaletter.com - October 16 at 11:35 PM
Eli Lilly says legislation to address drug prices would hurt its current, future operationsEli Lilly says legislation to address drug prices would hurt its current, future operations
wfyi.org - October 15 at 12:26 AM
Eli Lilly & Co Updates Verzenio Phase 3 MonarchE Trial Data Presented At ESMO Virtual Plenary And Simultaneously Published In Annals Of OncologyEli Lilly & Co Updates Verzenio Phase 3 MonarchE Trial Data Presented At ESMO Virtual Plenary And Simultaneously Published In Annals Of Oncology
benzinga.com - October 14 at 7:26 PM
BRIEF-Lilly Announces Updated Verzenio Phase 3 Monarche Trial Data Presented At Esmo Virtual Plenary And Simultaneously Published In The Annals Of OncologyBRIEF-Lilly Announces Updated Verzenio Phase 3 Monarche Trial Data Presented At Esmo Virtual Plenary And Simultaneously Published In The Annals Of Oncology
msn.com - October 14 at 7:26 PM
Olympian joins Eli Lilly to level the field for health inequity in breast cancerOlympian joins Eli Lilly to level the field for health inequity in breast cancer
fiercepharma.com - October 14 at 1:43 PM
Lilly Announces Updated Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Presented at ESMO Virtual Plenary and Simultaneously Published in the Annals of OncologyLilly Announces Updated Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Presented at ESMO Virtual Plenary and Simultaneously Published in the Annals of Oncology
finance.yahoo.com - October 14 at 1:43 PM
Eli Lilly gets USFDA nod to Verzenio as adjuvant therapy for breast cancer patientsEli Lilly gets USFDA nod to Verzenio as adjuvant therapy for breast cancer patients
medicaldialogues.in - October 14 at 8:43 AM
FDA approves Eli Lilly’s Verzenio in high risk early breast cancerFDA approves Eli Lilly’s Verzenio in high risk early breast cancer
pmlive.com - October 14 at 8:43 AM
FDA approves Eli Lilly breast cancer drugFDA approves Eli Lilly breast cancer drug
tristatehomepage.com - October 14 at 12:58 AM
Anticancer Drugs Market SWOT Analysis by Key Players AstraZeneca, Eli Lilly and Company, CELGENEAnticancer Drugs Market SWOT Analysis by Key Players AstraZeneca, Eli Lilly and Company, CELGENE
openpr.com - October 13 at 2:57 PM
FDA Greenlights Lilly Early Breast Cancer DrugFDA Greenlights Lilly Early Breast Cancer Drug
pharmalive.com - October 13 at 2:57 PM
BRIEF-Hemogenyx Pharma Signs Agreement With Eli LillyBRIEF-Hemogenyx Pharma Signs Agreement With Eli Lilly
msn.com - October 13 at 2:57 PM
Eli Lilly: FDA Approves Verzenio in Some High-Risk Early Breast-Cancer PatientsEli Lilly: FDA Approves Verzenio in Some High-Risk Early Breast-Cancer Patients
morningstar.com - October 13 at 2:57 PM
Eli Lilly Received FDA Approval Tuesday for Verzenio for Efficacy Under NDA 208716Eli Lilly Received FDA Approval Tuesday for Verzenio for Efficacy Under NDA 208716
benzinga.com - October 13 at 9:57 AM
Hemogenyx Signs Licensing Agreement With Eli Lilly for AntibodyHemogenyx Signs Licensing Agreement With Eli Lilly for Antibody
morningstar.com - October 13 at 9:57 AM
Eli Lillys Verzenio snags first-in-class FDA approval for early breast cancer. But limited label poses a challengeEli Lilly's Verzenio snags first-in-class FDA approval for early breast cancer. But limited label poses a challenge
fiercepharma.com - October 13 at 9:57 AM
FDA approves Eli Lilly pill as treatment for people with high-risk, early breast cancerFDA approves Eli Lilly pill as treatment for people with high-risk, early breast cancer
msn.com - October 13 at 9:57 AM
Eli Lilly, Boehringer roll out video game for doctors to highlight cardio-renal-metabolic disease connectionsEli Lilly, Boehringer roll out video game for doctors to highlight cardio-renal-metabolic disease connections
fiercepharma.com - October 12 at 6:38 PM
Premature Ejaculation Treatment Market 2021 Opportunities, Share, Trends And Forecast to 2030 | Pfizer, Bayer, Novartis, Vivus, Menarini, Eli LillyPremature Ejaculation Treatment Market 2021 Opportunities, Share, Trends And Forecast to 2030 | Pfizer, Bayer, Novartis, Vivus, Menarini, Eli Lilly
manometcurrent.com - October 12 at 1:37 PM
Eli Lilly and (NYSE:LLY) Upgraded to "Buy" by Berenberg BankEli Lilly and (NYSE:LLY) Upgraded to "Buy" by Berenberg Bank
marketbeat.com - October 11 at 7:06 AM
Eli Lilly and (NYSE:LLY) Upgraded to Buy at CitigroupEli Lilly and (NYSE:LLY) Upgraded to Buy at Citigroup
marketbeat.com - September 29 at 7:32 AM
The Top 3 Healthcare Dividend Stocks to Buy and Hold (LLY)The Top 3 Healthcare Dividend Stocks to Buy and Hold (LLY)
marketbeat.com - August 18 at 5:47 PM
DateCompanyBrokerageAction
10/12/2021NovartisBerenberg Bank
Reiterated Rating
10/12/2021Merck & Co., Inc.Morgan Stanley
Boost Price Target
10/11/2021AstraZenecaDeutsche Bank Aktiengesellschaft
Reiterated Rating
10/11/2021Eli Lilly andBerenberg Bank
Upgrade
10/10/2021Merck & Co., Inc.Berenberg Bank
Reiterated Rating
10/8/2021NovartisUBS Group
Reiterated Rating
10/8/2021Merck & Co., Inc.Barclays
Boost Price Target
10/4/2021Merck & Co., Inc.SVB Leerink
Boost Price Target
10/1/2021Merck & Co., Inc.Mizuho
Initiated Coverage
9/29/2021Eli Lilly andCitigroup
Upgrade
9/27/2021AstraZenecaSVB Leerink
Boost Price Target
9/24/2021Eli Lilly andJPMorgan Chase & Co.
Reiterated Rating
9/20/2021NovartisDeutsche Bank Aktiengesellschaft
Downgrade
9/20/2021AstraZenecaSVB Leerink
Boost Price Target
9/17/2021AstraZenecaMorgan Stanley
Reiterated Rating
9/7/2021Merck & Co., Inc.Morgan Stanley
Downgrade
9/2/2021AbbVieSVB Leerink
Lower Price Target
8/30/2021Eli Lilly andCowen
Boost Price Target
8/23/2021AbbVieCowen
Boost Price Target
8/20/2021AbbVieMorgan Stanley
Reiterated Rating
8/20/2021AbbVieSVB Leerink
Boost Price Target
8/12/2021AstraZenecaJPMorgan Chase & Co.
Initiated Coverage
8/9/2021AstraZenecaMorgan Stanley
Initiated Coverage
8/9/2021Eli Lilly andArgus
Boost Price Target
8/5/2021AbbVieArgus
Boost Price Target
8/5/2021Eli Lilly andDZ Bank
Upgrade
8/4/2021AstraZenecaSVB Leerink
Boost Price Target
8/4/2021Eli Lilly andJPMorgan Chase & Co.
Boost Price Target
8/4/2021Eli Lilly andMorgan Stanley
Boost Price Target
8/4/2021Eli Lilly andMizuho
Boost Price Target
8/2/2021AbbVieSVB Leerink
Boost Price Target
8/2/2021AbbVieMizuho
Boost Price Target
8/2/2021AbbVieBarclays
Boost Price Target
7/30/2021Merck & Co., Inc.SVB Leerink
Boost Price Target
7/28/2021NovartisJPMorgan Chase & Co.
Reiterated Rating
7/27/2021AbbVieTruist Securities
Initiated Coverage
7/27/2021AbbVieTruist
Initiated Coverage
7/27/2021Merck & Co., Inc.Truist Securities
Initiated Coverage
7/27/2021Merck & Co., Inc.Truist
Initiated Coverage
7/27/2021Eli Lilly andTruist
Initiated Coverage
7/22/2021NovartisDeutsche Bank Aktiengesellschaft
Downgrade
7/21/2021AstraZenecaCitigroup
Reiterated Rating
7/16/2021AstraZenecaSVB Leerink
Lower Price Target
7/7/2021Eli Lilly andMizuho
Reiterated Rating
7/6/2021Eli Lilly andBarclays
Boost Price Target
7/2/2021AbbVieDaiwa Capital Markets
Initiated Coverage
7/2/2021Eli Lilly andTruist Securities
Boost Price Target
7/2/2021Eli Lilly andTruist
Boost Price Target
6/24/2021Eli Lilly andCantor Fitzgerald
Boost Price Target
6/24/2021Eli Lilly andCowen
Boost Price Target
6/17/2021AstraZenecaUBS Group
Reiterated Rating
6/15/2021Eli Lilly andJPMorgan Chase & Co.
Boost Price Target
6/14/2021Eli Lilly andThe Goldman Sachs Group
Boost Price Target
6/9/2021Merck & Co., Inc.JPMorgan Chase & Co.
Lower Price Target
6/8/2021Eli Lilly andTruist Securities
Reiterated Rating
6/8/2021Eli Lilly andTruist Financial
Reiterated Rating
6/7/2021Merck & Co., Inc.Truist Securities
Lower Price Target
6/4/2021AstraZenecaSVB Leerink
Boost Price Target
6/3/2021Merck & Co., Inc.SVB Leerink
Lower Price Target
5/20/2021Merck & Co., Inc.Argus
Reiterated Rating
5/11/2021NovartisMorgan Stanley
Reiterated Rating
5/3/2021AbbVieBMO Capital Markets
Boost Price Target
5/3/2021AbbVieMizuho
Boost Price Target
4/30/2021AbbViePiper Sandler
Boost Price Target
4/30/2021Merck & Co., Inc.SVB Leerink
Lower Price Target
4/28/2021NovartisJPMorgan Chase & Co.
Reiterated Rating
4/28/2021NovartisOddo Bhf
Upgrade
4/28/2021Eli Lilly andMorgan Stanley
Lower Price Target
4/28/2021Eli Lilly andMizuho
Lower Price Target
4/28/2021Eli Lilly andBarclays
Lower Price Target
4/19/2021NovartisUBS Group
Reiterated Rating
4/19/2021AstraZenecaArgus
Reiterated Rating
4/12/2021AstraZenecaArgus
Downgrade
4/7/2021AbbVieRoyal Bank of Canada
Initiated Coverage
3/30/2021AbbVieSVB Leerink
Boost Price Target
3/23/2021NovartisSociete Generale
Reiterated Rating
3/23/2021AstraZenecaSociete Generale
Reiterated Rating
3/22/2021NovartisSanford C. Bernstein
Initiated Coverage
3/18/2021AstraZenecaDeutsche Bank Aktiengesellschaft
Reiterated Rating
3/16/2021NovartisArgus
Reiterated Rating
3/16/2021AstraZenecaJefferies Financial Group
Upgrade
3/15/2021Eli Lilly andTruist Securities
Boost Price Target
3/10/2021NovartisArgus
Downgrade
3/9/2021AstraZenecaBerenberg Bank
Reiterated Rating
3/8/2021AstraZenecaBarclays
Reiterated Rating
3/2/2021AstraZenecaSVB Leerink
Lower Price Target
2/25/2021AstraZenecaUBS Group
Upgrade
2/12/2021Eli Lilly andCowen
Boost Price Target
2/5/2021Merck & Co., Inc.Cantor Fitzgerald
Reiterated Rating
2/4/2021AbbVieSVB Leerink
Boost Price Target
2/4/2021AbbVieRoyal Bank of Canada
Boost Price Target
2/4/2021AbbVieMizuho
Boost Price Target
2/2/2021NovartisMorgan Stanley
Reiterated Rating
2/1/2021NovartisCowen
Downgrade
1/28/2021AbbVieMorgan Stanley
Lower Price Target
1/22/2021NovartisBarclays
Reiterated Rating
1/22/2021AstraZenecaBarclays
Reiterated Rating
1/15/2021NovartisDeutsche Bank Aktiengesellschaft
Initiated Coverage
1/15/2021AstraZenecaBerenberg Bank
Reiterated Rating
1/15/2021AstraZenecaDeutsche Bank Aktiengesellschaft
Initiated Coverage
1/8/2021NovartisMorgan Stanley
Reiterated Rating
12/30/2020AstraZenecaAlphaValue
Upgrade
12/16/2020AbbVieSVB Leerink
Boost Price Target
12/15/2020AbbVieMizuho
Boost Price Target
12/14/2020AstraZenecaUBS Group
Reiterated Rating
12/6/2020Merck & Co., Inc.Mizuho
Reiterated Rating
12/3/2020NovartisArgus
Boost Price Target
11/30/2020AbbVieMorgan Stanley
Boost Price Target
11/25/2020NovartisUBS Group
Reiterated Rating
11/18/2020AbbVieBMO Capital Markets
Initiated Coverage
11/10/2020AbbVieSanford C. Bernstein
Initiated Coverage
11/10/2020NovartisJPMorgan Chase & Co.
Reiterated Rating
11/10/2020Merck & Co., Inc.Sanford C. Bernstein
Reiterated Rating
10/29/2020Merck & Co., Inc.SVB Leerink
Boost Price Target
10/23/2020Merck & Co., Inc.Truist
Initiated Coverage
10/16/2020Merck & Co., Inc.JPMorgan Chase & Co.
Boost Price Target
9/29/2020NovartisBerenberg Bank
Initiated Coverage
9/29/2020Merck & Co., Inc.Berenberg Bank
Initiated Coverage
9/23/2020NovartisOddo Bhf
Downgrade
9/22/2020Merck & Co., Inc.Mizuho
Reiterated Rating
9/10/2020NovartisUBS Group
Upgrade
9/1/2020NovartisMorgan Stanley
Upgrade
8/25/2020Merck & Co., Inc.SVB Leerink
Boost Price Target
8/4/2020Merck & Co., Inc.Royal Bank of Canada
Reiterated Rating
8/3/2020Merck & Co., Inc.The Goldman Sachs Group
Upgrade
(Data available from 10/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.